Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Vilacto Bio’s Vilact Skin Cream Wins Award at Las Vegas ECRM Skin, Bath, Cosmetics & Natural Beauty EPPS


Posted on: 14 Jun 18

COPENHAGEN, Denmark, June 14, 2018 (GLOBE NEWSWIRE) -- Vilacto Bio Inc.’s (OTCQB:VIBI) Vilact skin cream won the buyers choice award at the recent ECRM Skin, Bath, Cosmetics & Natural Beauty EPPS (efficient program planning session) in Las Vegas, Nevada, USA.

The company had a very productive event over the 5 days conducting 70 meetings with interested vendors including some of the biggest retailers globally. The Company met with CVS, Kroger, Boots, Sally Beauty, Whole Foods Market and Wallgreens, and everyone appeared to like the product set. Vilacto Bio believe the presentation left these retailers with an appreciation of how the technology, creams and production worked. All the vendors where very excited by the company offering but also the vision of what the company are creating for the future with regard to anti-ageing and immune boosting Nano technology creams.

Vilacto Bio were also very pleased to have taken a number of orders from clients at the show that company believe will translate into substantial revenue going forward. Since the return from the event the company have been working with following up with everyone, sending samples and presentations.

Everyone at the event showed interest in our Carmen Electra By Vilact products and the Company hopes to receive orders imminently.

Vilact was honored with the ECRM and DSN Buyer’s Choice Award at the event. Buyers cast their votes based on product innovation and packaging.

“The interest in our products was great,” said Vilacto Bio CEO Gert Anderson. “We had 70 private meetings with buyers from a wide range of retail chains in the United States. Now we have a lot of follow up work to do and orders to fulfill.”

Vilact is based on Vilacto Bio’s Lactoactive®, a high-tech refined processing of colostrum, which contains a high proportion of immune-stimulating substances, growth substances, vitamins, minerals and enzymes. By reinforcing these, Vilact makes it possible for the final ingredients to work with the body’s own natural defenses.

The continued success of Vilact is a testament to the power of Lactoactive® and its pharma-grade derivative, Lactoactive® iTHER®. It also bears witness to Vilacto Bio’s growing distribution and commercialization capabilities.

About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTCQB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.

Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Vilacto Bio Inc.
The Seagram Building
375 Park Avenue, Suite 2607
New York City, NY 10152

Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com

GlobeNewswire
globenewswire.com

Last updated on: 14/06/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.